

CLINICAL VIGNETTE

Moyamoya Disease: An Important Non-Atherosclerotic Cause of Stroke Affecting the Young

Amanda Scott, MD and Anthony Wang, MD

Case

A 31-year-old female was referred for concern for Moyamoya disease (MMD). Two months prior to her visit, she suddenly developed a headache at work, with acute struggling with her speech. She was also nauseous and started vomiting, and a bystander called 911 and she was taken to a local hospital by ambulance. On imaging, she was found to have a 2-3 cm intracerebral hemorrhage centered in the left basal ganglia, and was started on anti-hypertensives; her initial systolic blood pressure was in the 150's mm Hg. She was also started on levetiracetam for seizure prophylaxis. A diagnostic cerebral angiogram showed bilateral Suzuki grade 5 MMD. MRI revealed remote bifrontal ischemic infarcts, and she was discharged to an inpatient rehabilitation facility, with neurologic deficits including mixed aphasia, dysarthria and mild right hemiparesis.

Prior to her presentation, she was generally healthy, though on review, she did have untreated seizures as a child. She had no prior surgeries, and no known family history of MMD. She is a non-smoker and uses no illicit drugs. Her discharge medications included amantadine, citalopram, levetiracetam, atorvastatin and clonidine, to maintain a blood pressure goal of <160/90 mm Hg.

On exam, her vital signs and general exam were normal with a blood pressure of 103/64 mm Hg. Her neurologic examination revealed 3/4 hyper-reflexia at the right patella and decreased sensation to two-point discrimination over the right lateral leg. Otherwise, sensation, reflexes, gait and strength had recovered to near-normal. She had a mixed trans-cortical aphasia including both expressive and receptive components, but with the help of family, she was able to answer questions in Korean. She was relaxed and pleasant. Her family reported that her language deficits were improving slowly at home. Prior to her stroke, she was fully fluent in Korean and English, but in rehabilitation she had re-gained only Korean speech, and her ability to write in English.

Four months after her stroke, she underwent cerebral revascularization via a combined superficial temporal artery (STA) to middle cerebral artery (MCA) bypass on the left side. Three months later, she returned to have a right direct STA-MCA bypass. She tolerated her surgeries well, though she temporarily experienced partial sensorineural hearing loss beginning several days after her second surgery that started on the right side, spread to involve the left side, and then reverted to just the

right side again, before dissipating within 2 weeks. She had no new strokes on MRI post-operatively and her donor vessels were patent. She was discharged with low-dose aspirin, as well as lacosamide for seizure prophylaxis. She has since fully regained her language function in both Korean and English, and her hemiparesis has fully resolved. She will have follow-up angiography 6 months, and yearly MRI/MRA thereafter.

Discussion

MMD is a chronic, idiopathic, bilateral, progressive stenooclusive arteriopathy characterized by stenosis of the terminal internal carotid arteries and the proximal middle and anterior cerebral arteries. As the stenosis progresses, the posterior cerebral arteries can become occluded as well.^{1,2} Compensatory dilation of collateral vasculature in the deep nuclei results in a hazy angiographic appearance that inspired the nickname "moyamoya," Japanese for "puff of smoke".³ MMD is definitively diagnosed by digital subtraction angiography, but MRI/MRA commonly identifies suspected cases. Suzuki and Takaku described six stages of angiographic evolution.⁴ While this grading system bears little correlation with clinical outcomes, it is still widely employed to describe disease progression.

Whereas MMD is idiopathic by definition,⁵ the terms "quasi-moyamoya" and "moyamoya syndrome" are typically used to describe the angiographic appearance of moyamoya in the setting of an associated disease or condition, such as sickle cell disease, type 1 neurofibromatosis, trisomy 21, cranial irradiation, or an autoimmune disorder, among many others. Atherosclerosis and vasculitis are inconsistently included with these associated conditions, though are often maintained separately in that prognosis and treatment are quite different for these cases. The distinction is critical in that, while MMD is expected to progress in a large majority of cases, certain forms of quasi-moyamoya may be halted with risk factor modification. Atherosclerosis is the most common of these. One area that remains unaddressed is the confluence of genetic predisposition and bone marrow transplantation in sickle cell patients, as affecting the risk of moyamoya syndrome development and progression.

In Korea, the prevalence of MMD was estimated to be 9.1 per 100,000 in 2008, with an incidence of 1 per 100,000. In com-

parison, the annual incidence of MMD in the states of Washington and California was 0.086 per 100,000 in 2005. MMD affects women more than men, at about a 2:1 ratio, and 10-15% of patients have a family history of MMD.² There are two peaks of incidence, one in childhood centered around the age of 10, and another around the age of 40.^{1,2,6}

MMD can present with transient ischemic symptoms, stroke, intracerebral hemorrhage, seizures, cognitive dysfunction or headaches. Since the anterior circulation is more commonly affected, the ischemic symptoms affecting these patients commonly involve hemiparesis, language dysfunction or sensory deficits.² Intracerebral hemorrhage occurs in about 30% of MMD patients, most commonly in adults, due to friable collateral vessels. One identified site of collateralization prone to hemorrhage is the choroidal anastomosis, which, when visualized, portends a dramatically greater risk of bleeding.⁷ Seizures occur in about 5% of MMD patients and are related to ischemia. Headaches in MMD are thought to be related to dilation of dural and cortical vasculature, with a mechanism similar to migraine headaches. Some children with MMD can develop choreiform movements, or a “morning glory” optic disk appearance.⁸ Posterior circulation disease is associated with a worsened prognosis. MMD should be suspected in young stroke or intracerebral hemorrhage patients with few risk factors for atherosclerotic disease.

A small number of genetic features predispose to MMD, the most important being a p.R4810K variation in the *RNF213* gene on the long arm of chromosome 17.⁹ Interestingly, the R4810K variant is largely specific to the East Asian population, while other variants of *RNF213* are associated with MMD, along with a number of other vascular disorders, in other parts of the world.¹⁰ Non-R4810K variants have also been associated with hemorrhagic presentation in MMD,¹¹ as well as intracranial atherosclerosis.¹²

The natural history of MMD includes a 65-95% risk of stroke recurrence within 5 years of initial stroke.¹³ Two-thirds of patients experience significant motor and cognitive decline over ten years' follow-up, if untreated.¹³ While low-dose aspirin, permissive hypertension, and aggressive oral fluid hydration are commonly initiated in MMD patients presenting with ischemic symptoms in an effort to mitigate short-term stroke recurrence, the treatment of MMD is surgical revascularization.^{4,14} Surgery is typically recommended in otherwise low-risk surgical patients with symptomatic Suzuki grade 2 angiographic moyamoya, or Suzuki grade 3 and above with or without symptoms. Goals of surgery include long-term stroke risk reduction, re-hemorrhagic risk reduction, preservation of motor and cognitive function, and rarely, seizure management. Long-term stroke risk and symptomatic progression are reduced to <5% after revascularization.¹⁵⁻¹⁷

A variety of techniques for surgical revascularization have been described, all with the goal of blood flow augmentation. In general, these revascularization techniques can be divided into two types: indirect, where an external source of arterial blood is

brought into close proximity with the brain in order to promote neoangiogenesis and collateralization; and direct, where an external source of blood is channeled directly into the recipient cerebral artery. While it is generally accepted, though with little evidence in support, that children with MMD likely respond just as well to indirect techniques as to direct,¹⁸ recent literature in adult patients with MMD has heavily favored strategies that include direct revascularization. These include combined revascularization involving both a direct and an indirect technique, in patients with either ischemic or hemorrhagic presentation.¹⁹⁻²³

It is increasingly clear that treatment at a high-volume center is among the most important predictors of surgical outcome, with patients experiencing shorter lengths of stay, lower costs, greater likelihood of discharge to home, and a 15-fold lower rate of death.^{24,25} In addition, while long-term maintenance of revascularization remains excellent,²⁶ MMD remains a systemic disease wherein disease progression continues despite symptomatic stability. As such, patients require long-term monitoring with surveillance imaging, clinical monitoring, and neuropsychological evaluations.

REFERENCES

1. **Duan L, Bao XY, Yang WZ, Shi WC, Li DS, Zhang ZS, Zong R, Han C, Zhao F, Feng J.** Moyamoya disease in China: its clinical features and outcomes. *Stroke*. 2012 Jan;43(1):56-60. doi: 10.1161/STROKEAHA.111.621300. Epub 2011 Oct 20. PMID: 22020027.
2. **Kim JS.** Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. *J Stroke*. 2016 Jan;18(1):2-11. doi: 10.5853/jos.2015.01627. Epub 2016 Jan 29. PMID: 26846755; PMCID: PMC4747069.
3. **Suzuki J, Takaku A.** Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. *Arch Neurol*. 1969 Mar;20(3):288-99. doi: 10.1001/archneur.1969.00480090076012. PMID: 5775283.
4. **Fujimura M, Bang OY, Kim JS.** Moyamoya Disease. *Front Neurol Neurosci*. 2016;40:204-220. doi: 10.1159/000448314. Epub 2016 Dec 2. PMID: 27960175.
5. **Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases.** Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). *Neurol Med Chir (Tokyo)*. 2012;52(5):245-66. doi: 10.2176/nmc.52.245. PMID: 22870528.
6. **Baba T, Houkin K, Kuroda S.** Novel epidemiological features of moyamoya disease. *J Neurol Neurosurg Psychiatry*. 2008 Aug;79(8):900-4. doi: 10.1136/jnnp.2007.130666. Epub 2007 Dec 12. PMID: 18077479.
7. **Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S.** High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. *J*

- Neurosurg.* 2019 Feb 1;130(2):337-673. doi: 10.3171/2017.9.JNS17576. Epub 2018 Mar 2. PMID: 29498573.
8. **Massaro M, Thorarensen O, Liu GT, Maguire AM, Zimmerman RA, Brodsky MC.** Morning glory disc anomaly and moyamoya vessels. *Arch Ophthalmol.* 1998 Feb;116(2):253-4. PMID: 9488287.
 9. **Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH, Fujiyama A, Herzig R, Kricshek B, Zou L, Kim JE, Kitakaze M, Miyamoto S, Nagata K, Hashimoto N, Koizumi A.** Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. *PLoS One.* 2011;6(7):e22542. doi: 10.1371/journal.pone.0022542. Epub 2011 Jul 20. PMID: 21799892; PMCID: PMC3140517.
 10. **Cecchi AC, Guo D, Ren Z, Flynn K, Santos-Cortez RL, Leal SM, Wang GT, Regalado ES, Steinberg GK, Shendure J, Bamshad MJ; University of Washington Center for Mendelian Genomics, Grotta JC, Nickerson DA, Pannu H, Milewicz DM.** RNF213 rare variants in an ethnically diverse population with Moyamoya disease. *Stroke.* 2014 Nov;45(11):3200-7. doi: 10.1161/STROKEAHA.114.006244. Epub 2014 Oct 2. PMID: 25278557; PMCID: PMC4420622.
 11. **Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, Song D, Zhang J, Guan M, Gu Y.** Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. *PLoS One.* 2012;7(10):e48179. doi: 10.1371/journal.pone.0048179. Epub 2012 Oct 23. PMID: 23110205; PMCID: PMC3479116.
 12. **Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, Nakatomi H, Shimizu T, Saito N.** Genetic variant RNF213 c.14576G>A in various phenotypes of intracranial major artery stenosis/occlusion. *Stroke.* 2013 Oct;44(10):2894-7. doi: 10.1161/STROKEAHA.113.002477. Epub 2013 Aug 22. PMID: 23970789.
 13. **Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y.** Incidence and clinical features of disease progression in adult moyamoya disease. *Stroke.* 2005 Oct;36(10):2148-53. doi: 10.1161/01.STR.0000182256.32489.99. Epub 2005 Sep 22. PMID: 16179571.
 14. **Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC; JAM Trial Investigators.** Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. *Stroke.* 2014 May;45(5):1415-21. doi: 10.1161/STROKEAHA.113.004386. Epub 2014 Mar 25. PMID: 24668203.
 15. **Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM, Marks MP, Steinberg GK.** Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. *J Neurosurg.* 2009 Nov;111(5):927-35. doi: 10.3171/2009.4.JNS081649. PMID: 19463046.
 16. **Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA.** Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. *J Neurosurg.* 2004 Feb;100(2 Suppl Pediatrics):142-9. doi: 10.3171/ped.2004.100.2.0142. PMID: 14758941.
 17. **Imaizumi T, Hayashi K, Saito K, Osawa M, Fukuyama Y.** Long-term outcomes of pediatric moyamoya disease monitored to adulthood. *Pediatr Neurol.* 1998 Apr;18(4):321-5. doi: 10.1016/s0887-8994(97)00209-9. PMID: 9588527.
 18. **Matsushima T, Inoue T, Suzuki SO, Fujii K, Fukui M, Hasuo K.** Surgical treatment of moyamoya disease in pediatric patients--comparison between the results of indirect and direct revascularization procedures. *Neurosurgery.* 1992 Sep;31(3):401-5. doi: 10.1227/00006123-199209000-00003. PMID: 1407421.
 19. **Kawaguchi S, Okuno S, Sakaki T.** Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease. *J Neurosurg.* 2000 Sep;93(3):397-401. doi: 10.3171/jns.2000.93.3.0397. PMID: 10969936.
 20. **Kim DS, Huh PW, Kim HS, Kim IS, Choi S, Mok JH, Huh CW.** Surgical treatment of moyamoya disease in adults: combined direct and indirect vs. indirect bypass surgery. *Neurol Med Chir (Tokyo).* 2012;52(5):333-8. doi: 10.2176/nmc.52.333. PMID: 22688071.
 21. **Sun H, Wilson C, Ozpinar A, Safavi-Abbasi S, Zhao Y, Nakaji P, Wanebo JE, Spetzler RF.** Perioperative Complications and Long-Term Outcomes After Bypasses in Adults with Moyamoya Disease: A Systematic Review and Meta-Analysis. *World Neurosurg.* 2016 Aug;92:179-188. doi: 10.1016/j.wneu.2016.04.083. Epub 2016 May 2. PMID: 27150649.
 22. **Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, Cao Y, Zhao Y, Pan Y, Liu X, Zhang Q, Zhao J.** Direct versus indirect bypasses for adult ischemic-type moyamoya disease: a propensity score-matched analysis. *J Neurosurg.* 2018 Jun;128(6):1785-1791. doi: 10.3171/2017.2.JNS162405. Epub 2017 Aug 11. PMID: 28799875.
 23. **Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW.** Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. *J Neurosurg.* 2018 Mar;128(3):793-799. doi: 10.3171/2016.11.JNS161688. Epub 2017 May 5. PMID: 28474994.
 24. **Bekelis K, Connolly ID, Do HM, Choudhri O.** Operative volume and outcomes of cerebrovascular neurosurgery in children. *J Neurosurg Pediatr.* 2016 Nov;18(5):623-628. doi: 10.3171/2016.5.PEDS16137. Epub 2016 Aug 5. PMID: 27494548.
 25. **Titworth WL, Scott RM, Smith ER.** National Analysis of 2454 Pediatric Moyamoya Admissions and the Effect of Hospital Volume on Outcomes. *Stroke.* 2016 May;47(5):1303-11. doi: 10.1161/STROKEAHA.115.012168. Epub 2016 Apr 5. PMID: 27048697.
 26. **Riordan CP, Storey A, Cote DJ, Smith ER, Scott RM.** Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis. *J Neurosurg Pediatr.* 2019 Mar 1:1-7. doi:

10.3171/2019.1.PEDS18457. Epub ahead of print. PMID:
30835683.